The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics
- PMID: 18061880
- DOI: 10.1016/j.drudis.2007.10.002
The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics
Abstract
Lack of predictability of clinical efficacy and safety is an important problem facing pharmaceutical research today. Translational PK-PD has the ability to integrate data generated from diverse test platforms during discovery and development in a mechanistic framework. Therefore, successful implementation of translational PK-PD modelling and simulation early in the development cycle could have a substantial impact on overall efficiency and success of pharmaceutical research. Three case studies are presented, which outline successful implementation of the translational PK-PD methodology in the rational development of biotherapeutics across various stages of discovery and development. Emerging developments within the field are also discussed.
Similar articles
-
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.Trends Pharmacol Sci. 2008 Apr;29(4):186-91. doi: 10.1016/j.tips.2008.01.007. Epub 2008 Mar 18. Trends Pharmacol Sci. 2008. PMID: 18353445 Review.
-
PK/PD modelling and simulations: utility in drug development.Drug Discov Today. 2008 Apr;13(7-8):341-6. doi: 10.1016/j.drudis.2008.01.003. Epub 2008 Mar 7. Drug Discov Today. 2008. PMID: 18405847 Review.
-
[Role of pharmacokinetic-pharmacodynamic relationships in drug development].Therapie. 2002 Jul-Aug;57(4):347-57. Therapie. 2002. PMID: 12422555 French.
-
Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine.J Vet Pharmacol Ther. 2004 Dec;27(6):467-77. doi: 10.1111/j.1365-2885.2004.00613.x. J Vet Pharmacol Ther. 2004. PMID: 15601441 Review.
-
Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.J Pharm Sci. 2012 Dec;101(12):4367-82. doi: 10.1002/jps.23330. Epub 2012 Sep 27. J Pharm Sci. 2012. PMID: 23018763 Review.
Cited by
-
Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1.J Pharmacokinet Pharmacodyn. 2020 Oct;47(5):513-526. doi: 10.1007/s10928-020-09702-3. Epub 2020 Jul 24. J Pharmacokinet Pharmacodyn. 2020. PMID: 32710210 Free PMC article.
-
Using quantitative systems pharmacology to evaluate the drug efficacy of COX-2 and 5-LOX inhibitors in therapeutic situations.NPJ Syst Biol Appl. 2018 Aug 3;4:28. doi: 10.1038/s41540-018-0062-3. eCollection 2018. NPJ Syst Biol Appl. 2018. PMID: 30083389 Free PMC article.
-
Multi-Organs-on-Chips: Towards Long-Term Biomedical Investigations.Molecules. 2019 Feb 14;24(4):675. doi: 10.3390/molecules24040675. Molecules. 2019. PMID: 30769788 Free PMC article. Review.
-
Prediction of exposure-response relationships to support first-in-human study design.AAPS J. 2010 Dec;12(4):750-8. doi: 10.1208/s12248-010-9236-7. Epub 2010 Oct 22. AAPS J. 2010. PMID: 20967521 Free PMC article. Review.
-
Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody.AAPS J. 2008 Jun;10(2):425-30. doi: 10.1208/s12248-008-9045-4. Epub 2008 Aug 7. AAPS J. 2008. PMID: 18686041 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources